Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide

Richard A. Evans, Nicole M. Somers, Colin R. Dunstan, Ellen Hills, Mary Evans

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    The purpose of this study was to establish the smallest dose of nasally administered salmon calcitonin (SCT) which, if given in conjunction with a previously published calcium/thiazide treatment, would be as effective as parenteral SCT in the treatment of Paget's disease of bone. Forty patients suffering from symptomatic Paget's disease were treated with 0.5 g calcium three times daily, 10 mg/day clopamide, and 400 IU nasally administered salmon calcitonin given once or twice weekly. This regimen was given for 5 months, after which all treatment was ceased for 4 months. Parenteral SCT (100 IU) was then given three times weekly for 5 months to 25 of the patients. With the oral/nasal treatment, the plasma alkaline phosphatase level (AP) decreased by 30±15 (SD) % when the SCT was given once weekly and by 39±11% (P<0.05) when the SCT was given twice weekly. There were similar decreases in the fasting urinary hydroxyproline: creatinine ratios. The parenteral SCT reduced the AP by 33±23%. Though reduction in bone pain was similar with both treatments, most patients preferred the oral/nasal treatment. It is concluded that the oral/nasal treatment, when the SCT is given twice weekly, has similar efficacy to parenteral SCT, and is a well tolerated, effective initial treatment for Paget's disease of bone.

    Original languageEnglish
    Pages (from-to)164-167
    Number of pages4
    JournalCalcified Tissue International
    Volume49
    Issue number3
    DOIs
    Publication statusPublished - 01 May 1991

    Fingerprint Dive into the research topics of 'Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide'. Together they form a unique fingerprint.

    Cite this